Plo Pharmaceuticals: has completed the clinical enrollment for two indications of semaglutide for weight reduction and glycemic control.

On March 31st, Puruo Pharmaceuticals stated during the performance briefing that the company has completed the clinical enrollment for Sulotide for weight loss and blood sugar reduction indications. The company will strictly follow clinical trial standards and drug approval processes to expedite product launch.